Payment overview · 2025
General Payments
$635.03
31 reported records · 11 companies
Healthcare provider profile · identity verified
Allen Avedian, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TEMPLETON, CA · NPI 1003340423
Verified facts
What the public records show
CMS Open Payments records show Allen Avedian, M.D. received $635.03 in general payments during 2025 across 31 reported records.
GlaxoSmithKline, LLC. accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $104.64 | 16.5% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $97.61 | 15.4% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $85.04 | 13.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.20 | 12.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $67.82 | 10.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.97 | 7.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.08 | 6.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.26 | 5.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.19 | 4.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.21 | 4.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25.01 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $635.03 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $104.64 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $85.04 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.20 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $73.76 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $58.84 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.08 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.41 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.17 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.17 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.21 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 598 | 183 |
| Lisinopril | Lisinopril | 429 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 404 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 363 | 104 |
| Losartan Potassium | Losartan Potassium | 249 | 82 |
| Metformin Hcl | Metformin Hcl | 244 | 77 |
| Simvastatin | Simvastatin | 209 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 202 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 200 | 58 |
| Gabapentin | Gabapentin | 166 | 48 |
| Omeprazole | Omeprazole | 155 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 30 |
| Trazodone Hcl | Trazodone Hcl | 106 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 100 | 22 |
| Baclofen | Baclofen | 96 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 95 | 26 |
| Eliquis | Apixaban | 91 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 17 |
| Furosemide | Furosemide | 76 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 18 |
| Alprazolam | Alprazolam | 71 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 19 |
| Bupropion Xl | Bupropion Hcl | 66 | 15 |
| Allopurinol | Allopurinol | 62 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 17 |
| Sertraline Hcl | Sertraline Hcl | 62 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 26 |
| Lorazepam | Lorazepam | 61 | 17 |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Carvedilol | Carvedilol | 57 | 14 |
| Finasteride | Finasteride | 55 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 18 |
| Montelukast Sodium | Montelukast Sodium | 51 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | 24 |
| Sildenafil Citrate | Sildenafil Citrate | 49 | 14 |
| Tramadol Hcl | Tramadol Hcl | 49 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 47 | 19 |
| Potassium Chloride | Potassium Chloride | 46 | 14 |
| Prednisone | Prednisone | 45 | 13 |
| Ozempic | Semaglutide | 44 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 14 |
| Alendronate Sodium | Alendronate Sodium | 39 | 12 |
| Carisoprodol | Carisoprodol | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 16 |
| Ezetimibe | Ezetimibe | 36 | 13 |
| Spironolactone | Spironolactone | 36 | 11 |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Atenolol | Atenolol | 34 | 11 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Acyclovir | Acyclovir | 29 | 12 |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 18 |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $635.03 · 31 records | GlaxoSmithKline, LLC. | ABRYSVO, COMIRNATY, CREON, Cologuard Collection Kit, EVENITY, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error